Global Animal Model For Testing Market Size, Share, Opportunities, And Trends By Type Of Animal Model (Mice, Rats, Guinea Pigs, Rabbits, Monkeys), By Application Area (Pharmaceutical Industry, Biomedical Research, Cosmetics And Personal Care Product Testing, Toxicology Testing), By Services (Breeding Services, Quarantine And Pathogen Testing Services, Technical Services), And By Geography - Forecasts From 2024 To 2029

  • Published : Jan 2024
  • Report Code : KSI061616536
  • Pages : 146

The animal model for testing market is expected to witness significant growth during the forecasted period.

Animal models are commonly used to test the effects of diseases under different conditions and environments. This method of testing is also known as VIVO testing and is conducted by laboratories to study the behaviour or biological system of different animals in different conditions set by the researchers. Animals that have similar anatomical and physiological features to humans are commonly used for animal experimentation. Before a drug is administered to human subjects, the drug undergoes rigorous animal trials to evaluate its toxicity, metabolism, and overall efficacy. These include vertebrate animals such as rodents, primates, dogs, and rabbits. Mice are the most common vertebrate species used in VIVO testing, due to characteristics such as size, ease of handling, fast reproduction, and low cost. They are also known to share 95% of their genes with humans, making them a suitable animal model for VIVO testing purposes and evaluation of the safety and efficacy of the drug candidates at their preclinical stages.


The animal model for testing market growth is attributed to factors such as the increasing burden of zoonotic diseases. The core purpose of animal models is the testing of drug candidates and environmental conditions for analysis and creation of insights, which are further used for the generation of solutions for the future. For instance, during the COVID-19 pandemic, various animals were used for the VIVO testing process, which includes non-human primates such as genetically modified mice (wild-type mice sensitized by Ad5 or AAV vectors consisting of the hACE2 gene), as well as Syrian hamster, ferret, poultry, and domestic animals. Through the use of these animals, laboratories were able to summarize the benefits and defects of the SaRS-CoV-2 receptors and proteases, which eventually led to the creation of several vaccines around the world.

Market Drivers:

  • Increasing burden of zoonotic diseases: Zoonotic diseases, also known as zoonoses, are diseases that are derived from animals that affect the environment and the human body. Zoonoses come in different types, which include viral, bacterial, mycotic, parasitic, and unconventional (prions). Some of the common zoonoses that are known to mankind include diseases such as rabies, which is acquired through mammals; blastomycosis, which is acquired through inhalation of fungus spores; psittacosis, which is acquired from companion birds kept as pets by humans; and cat scratch disease, which is acquired through scratching or biting from cats. One of the well-known zoonotic diseases includes the COVID-19 pandemic, which was caused by SARS-CoV-2 from bats. One of the major factors that led to the increase in the animal models for the testing market growth is the increasing burden of zoonotic diseases worldwide.  As per the Council on Foreign Relations, 75% of the new emerging infectious diseases (EIDs) and 60% of the known infectious diseases are found to be zoonotic in nature. The increase in globalization, which includes population growth, intensified farming practices, trade of domesticated and wild animals, and environmental degradation such as climate change, habitat destruction, and deforestation, has intensified the wild and domesticated animal-human interface, which in turn increased the risk of zoonoses spillover. Instances such as the COVID-19 pandemic displayed the wider range, large, and more costly effects of low preparation to the reduction of risk of zoonoses worldwide. Due to the rising prevalence of zoonoses, the need for animal models is expected to also increase, which in turn boosts the VIVO testing or animal models for testing market and is expected to display significant growth potential during the forecasted period of 2024-2029.

Key Players:

  • Syngene International Limited: An American company that is known for being a contract research, development, and manufacturing organization (CRDMO) that provides several integrated services to companies in multiple sectors such as pharmaceutical, biotechnology, consumer goods, agrochemical, and animal healthcare industries.
  • PsychoGenics, Inc.: An American company that is known for being a contract research organization (CRO) that focuses on the central nervous system (CNS), which includes the designing and execution of preclinical drug synthesis and early development programs. They combine behavioural neurobiology with bioinformatics and proprietary behaviour testing platforms to test compound libraries for central nervous system (CNS) activity. They are also known to provide several varieties of mouse animal models that can support different areas of research.

Regional Analysis:

The North American region is expected to witness significant growth in the animal model for testing market during the forecasted period of 2024-2029 due to factors such as strong research capabilities and strong healthcare systems affecting the market growth in this region.  The use of animals such as mice, rats, guinea pigs, rabbits, and monkeys is common in animal experimentation of diseases and drugs. The support of establishments such as the American Physiological Society, Americans for Medical Progress, and American Society of Animal Science helps increase the effectiveness of animal experimentation, improve preparation for unknown diseases and introduce drugs and products to the general public. The United States is also known for having a strong healthcare infrastructure. For instance, as per Research America, the United States medical and health research and development investment reached US$245.1 billion in 2020, which is an 11.1% increase from 2019. The increase in medical and health R&D in the region provides a major boost to the animal model for the testing market growth during the forecasted period, which provides opportunities in the market for better and innovative methods of VIVO testing and improving the risk reduction of zoonoses.


  • By Type of Animal Model:
    • Mice
    • Rats
    • Guinea Pigs
    • Rabbits
    • Monkeys
  • By Application Area:
    • Pharmaceutical Industry
    • Biomedical Research
    • Cosmetics and Personal Care Product Testing
    • Toxicology Testing
  • By Services:
    • Breeding Services
    • Quarantine and Pathogen Testing Services
    • Technical Services
  • By Geography:
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Mice

5.3. Rats

5.4. Guinea Pigs

5.5. Rabbits

5.6. Monkeys


6.1. Introduction

6.2. Pharmaceutical Industry

6.3. Biomedical Research

6.4. Cosmetics and Personal Care Product Testing

6.5. Toxicology Testing


7.1. Introduction

7.2. Breeding Services

7.3. Quarantine and Pathogen Testing Services

7.4. Technical Services


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations


10.1. Syngene International Limited

10.2. PsychoGenics, Inc. 

10.3. Pharmaron

10.4. Pharmalegacy Laboratories

10.5. Beijing Vitalstar Biotechnology Co., Ltd.

Syngene International Limited

PsychoGenics, Inc.


Pharmalegacy Laboratories

Beijing Vitalstar Biotechnology Co., Ltd